POST (Parliamentary Office of Science and Technology)
Antimicrobial Resistance and Immunisation
A POSTnote that describes the potential for immunisation as a strategy to tackle antimicrobial resistance, both globally and in the UK. It discusses public health priority areas, the role for existing vaccines and the development of new ones.
Antimicrobial resistance (AMR) is an urgent global health threat that, if left unchecked, could account for an estimated 10 million deaths per year by 2050. A report commissioned by the UK Government and published in 2016 concluded that vaccines have been overlooked as a tool to reduce AMR and should be an investment focus.
Immunisation can reduce the AMR burden by preventing infections (including resistant ones) and therefore reducing antibiotic use, a major driver of resistance. This effect has already been seen for vaccines against pneumococcal and influenza infections. There are global differences in vaccine need and the challenges in using immunisation to reduce AMR.
There are two main approaches to this strategy: maximising the utility of existing vaccines by ensuring good uptake and offering them more widely as appropriate, and making decisions about which vaccines should be developed and introduced and when and where to use them most efficiently. Evaluating the impact and cost-effectiveness of a vaccine is an essential step in its use and introduction but how to value a vaccine in the context of AMR is complex and subject to ongoing research.
- Antimicrobial resistance (AMR) has reached a point where some infections may become untreatable.
- Immunisation is one strategy to tackle AMR, by decreasing rates of infection and thereby antibiotic use and preventing the development of resistant infections.
- The World Health Organization has developed a list of pathogens where AMR is of most concern and new antibiotics are needed; there is no equivalent for vaccines.
- Quantifying the impact of immunisation on AMR and incorporating this into calculating the cost-effectiveness of vaccines is still an area of ongoing research.
- Using immunisation to tackle AMR depends on wider use and increased uptake of existing vaccines, and increasing the development of new ones.
POSTnotes are based on literature reviews and interviews with range of stakeholders, and are externally peer reviewed. POST would like to thank interviewees and peer reviewers for kindly giving up their time during the preparation of this briefing, including:
Professor David Livermore, University of East Anglia*
Professor Marc Lipsitch, Harvard TH Chan School of Public Health*
Professor David Salisbury, Centre on Global Health Security, Chatham House*
Professor Andrew Pollard, University of Oxford and Chair of the Joint Committee on Vaccination and Immunisation*
Dr Katie Atkins, Professor John Edmunds, Dr Stefan Flasche and Professor Mark Jit, London School of Hygiene and Tropical Medicine*
Dr Michael Edelstein, Public Health England*
Professor Jeffrey Almond, University of Oxford
Kevin Outterson, Professor of Law, Boston University & Executive Director, CARB-X*
Professor Steve Black, Cincinnati Children's Hospital Medical Centre*
Dr E. David McIntosh, Imperial College London*
Dr Elizabeth Klemm and Dr Zoe Seager, The Wellcome Trust*
Professor Adam Cunningham, University of Birmingham and The BactiVac Network*
Dr Shamez Ladhani, Public Health England*
Department of Health and Social Care*
Dr Martin Friede, World Health Organization
Professor Ben Cooper, Nuffield Department of Medicine, University of Oxford*
Department for International Development*
Dr Marco Cavaleri, European Medicines Agency*
Association of the British Pharmaceutical Industry*
Andrew Earnshaw, Joint Committee on Vaccination and Immunisation
Dr Alberto Giubilini, Oxford Martin School and Wellcome Centre for Ethics and Humanities, University of Oxford
Dr Richard Pebody, Public Health England*
Dr Jonathan Pearce, Medical Research Council*
Dr Padmini Srikantiah, The Gates Foundation*
Professor Rino Rappuoli, GlaxoSmithKline Vaccines and Imperial College London*
*Denotes those who acted as external reviewers of the briefing.
|Academic Fellowships||Upcoming work||POST Publications|
Latest News from
POST (Parliamentary Office of Science and Technology)
Reducing UK Antibiotic Use in Animals09/10/2018 14:05:00
This POSTnote discusses the current use of antibiotics in animals and the options available for reducing that use.
Flexible Electricity Systems03/10/2018 16:20:00
The electricity system of Great Britain is becoming increasingly decentralised, with more complex patterns of power production, transportation and consumption.
Sleep and Health20/09/2018 16:25:00
A POSTnote that explains what is known about sleep and sleep disorders, the effects of poor sleep on performance, and on physical and mental health.
Shift Work, Sleep and Health20/09/2018 13:28:00
A POSTnote that describes how working outside of daytime hours – shift work – affects physical and mental health and performance through its impact on sleep and circadian timing.
Security of UK Telecommunications23/08/2018 15:15:15
Telecommunications networks are essential for the day-to-day running of UK businesses and public services, however, concerns have been raised recently over their security.
Developing Non-Academic Skills23/08/2018 13:25:00
Non-academic skills exist alongside academic knowledge and abilities, and can include empathy, communication, and resilience.
Unpaid Care20/07/2018 13:32:00
This POSTnote looks at the numbers of unpaid carers across the UK, and the amount and type of care provided. It examines the impacts of providing unpaid care on carers’ education, employment, finances, health and wellbeing, and personal and social relationships.
Small Modular Nuclear Reactors18/07/2018 16:25:00
There is growing UK and international interest in using ‘small modular nuclear reactors’ (SMRs) to generate electricity, and the UK Government announced a number of measures to support SMR development in the 2018 Nuclear Sector Deal.